Description:
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary
(de novo) GB that has recurred or progressed (first or second recurrence, including this
recurrence) after treatment(s) including surgery and radiotherapy with or without
chemotherapy and following discontinuation of any previous standard or investigational lines
of therapy.
Title
- Brief Title: Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
- Official Title: An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Clinical Trial IDs
- ORG STUDY ID:
MDNA55-05
- NCT ID:
NCT02858895
Conditions
- Glioblastoma
- Grade IV Astrocytoma
- Glioblastoma Multiforme
- Grade IV Glioma
Interventions
Drug | Synonyms | Arms |
---|
MDNA55 | IL4-PE, Interleukin-4 Pseudomonas Exotoxin, Interleukin-4 Pseudomonas Toxin, IL4 Pseudomonas Exotoxin, NBI-3001, cpIL4-PE | MDNA55 |
Purpose
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary
(de novo) GB that has recurred or progressed (first or second recurrence, including this
recurrence) after treatment(s) including surgery and radiotherapy with or without
chemotherapy and following discontinuation of any previous standard or investigational lines
of therapy.
Detailed Description
The study drug, MDNA55, is a fusion protein comprising a genetically engineered Interleukin-4
(IL-4) linked to a modified version of the Pseudomonas aeruginosa exotoxin A (PE). MDNA55
binds to the IL-4 receptor (IL4R), over-expressed by cancer cells and non-malignant
immunosuppressive cells of the tumor microenvironment (TME), and delivers a potent
cell-killing agent, PE.
The study will be conducted at up to 10 clinical sites following institutional review board
approval and completed informed consent.
Subjects that meet the study eligibility criteria will undergo surgery associated with study
drug administration. MDNA55 will be administered locally by convection-enhanced delivery
(CED).
Post-treatment follow-up assessment of safety and efficacy will be performed monthly for the
first 6 months and bimonthly thereafter for approximately 1 year after study drug
administrations. Subjects will continued to be followed for survival and post-study
treatment(s) of GB after study completion or withdrawal.
Trial Arms
Name | Type | Description | Interventions |
---|
MDNA55 | Experimental | Single infusion of MDNA55 via convection enhanced delivery (CED).*
*Subjects may be eligible to receive a second administration of MDNA55. | |
Eligibility Criteria
INCLUSION CRITERIA:
1. Subjects must be ≥ 18 years old and have a life expectancy ≥ 12 weeks
2. Histologically proven, primary (de novo) GB that has recurred or progressed (first or
second recurrence, including this recurrence)
3. Confirmation that archived tissue is available from first diagnosis of GB for
biomarker analysis
4. Recurrent tumor must be supratentorial, contrast-enhancing GB no smaller than 1 cm x 1
cm (largest perpendicular dimensions) and no larger than 4 cm maximum in a single
direction based on MRI taken within 14 days prior to catheter placement
5. Karnofsky Performance Score (KPS) ≥ 70
6. Subjects must be able and willing to undergo multiple brain MRI examinations
7. Subjects must be able and willing to comply with all study procedures
8. Any related toxicities following discontinuation of prior GB therapies must have
resolved to CTCAE Grade 1 or lower prior to inclusion in this study
EXCLUSION CRITERIA:
1. Prior treatment with cytotoxic chemotherapy
1. Temozolomide (standard induction and / or maintenance dosing) within the past 4
weeks prior to planned infusion
2. "Metronomic" Temozolomide (low-dose, continuous administration) within the past 7
days prior to planned infusion
3. Nitrosoureas within the past 6 weeks prior to planned infusion
4. Treatment with any other cytotoxic agent within the past 4 weeks prior to planned
infusion
2. Prior investigational treatment within the past 4 weeks or prior immunotherapy or
antibody therapy within the past 4 weeks prior to planned infusion
3. Prior treatment with bevacizumab (Avastin) or other vascular-endothelial growth factor
(VEGF) inhibitors or VEGF-receptor signaling inhibitors within the past 4 weeks prior
to planned infusion
4. Prior therapy that included interstitial brachytherapy or Gliadel® Wafers (carmustine
implants) within the past 12 weeks prior to planned infusion
5. Prior surgery (including stereotactic radiosurgery and biopsy procedures) within the
past 4 weeks prior to planned infusion
6. Ongoing Optune© therapy within 5 days of planned infusion
7. Secondary GB (i.e., GB that progressed from low-grade diffuse astrocytoma or AA)
8. Known mutation in either the isocitrate dehydrogenase 1 (IDH1) or the IDH2 gene.
9. Tumor in the brainstem (not including fluid-attenuated inversion recovery [FLAIR]
changes), an infratentorial tumor, diagnosis of gliomatosis cerebri (highly
infiltrative T2 hyperintense tumor with ill-defined margins encompassing at least
three lobes of the brain.
10. Tumor with a mass effect (e.g. 1-2 cm midline shift)
11. Subjects with tumors for which the preponderance of tissue is not of the type in which
convection would be possible (e.g. preponderance of cystic component)
12. Tumor with geometric features that make them difficult to adequately cover the tumor
volume with infusate by using CED catheters
13. Clinical symptoms that are thought by the Investigator to be caused by uncontrolled
increased intracranial pressure, hemorrhage, or edema of the brain
14. Any condition that precludes the administration of anesthesia
15. Known to be human immunodeficiency virus positive
16. Concurrent or a history of any significant medical illnesses that in the
Investigator's opinion cannot be adequately controlled with appropriate therapy or
would compromise the subject's ability to tolerate the study drug therapy and/or put
the subject at additional risk or interfere with the interpretation of the results of
this trial
17. Known history of allergy to gadolinium contrast agents
18. Presence of another type of malignancy requiring treatment within < 3 years prior to
the screening visit, except for adequately treated carcinoma in-situ of the cervix,
prostate cancer not actively treated, and basal or squamous cell carcinoma of the skin
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Survival (OS) |
Time Frame: | 12 months |
Safety Issue: | |
Description: | OS, time from treatment until death |
Secondary Outcome Measures
Measure: | Objective Response Rate (ORR) |
Time Frame: | 12 months |
Safety Issue: | |
Description: | ORR, determined by independent central review (per RANO-based criteria) |
Measure: | Progression Free Survival (PFS) |
Time Frame: | 12 months |
Safety Issue: | |
Description: | PFS, time from treatment until disease progression (per RANO-based criteria) or death |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Medicenna Therapeutics, Inc. |
Trial Keywords
- High grade glioma
- malignant glioma
- recurrent glioblastoma
- recurrent GBM
- recurrent GB
- glioblastoma (GB)
- glioblastoma multiforme (GBM)
- progressive glioblastoma
- Brain tumor
- Brain cancer
- immunotherapy
- targeted
- IL4R
Last Updated
January 15, 2021